Celldex Therapeutics Inc.
CLDX
Market Cap$2.15B
Close$
$-4.64
112.5% downside
Current Fair Value
112.5% downsideOvervalued by 112.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.15 Billion |
|---|---|
| Enterprise Value | $1.73 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.92 |
| Beta | 1.03 |
| Outstanding Shares | 55,900,679 |
| Avg 30 Day Volume | 652,921 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -15.23 |
|---|---|
| PEG | -23.98 |
| Price to Sales | - |
| Price to Book Ratio | 5.29 |
| Enterprise Value to Revenue | 251.38 |
| Enterprise Value to EBIT | -12.18 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Celldex Therapeutics Inc.
CEO: Anthony Marucci Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeu...